Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.

Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes

The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults

First-in-human trial in US for Gan & Lee type 2 diabetes drug

The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers

FDA clears Dexcom’s Stelo as first OTC Continuous Glucose Monitor for kids

Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format

Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials

The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions